Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review
JMIR Research Protocols · 2025
DOI: 10.2196/57256 ↗Kurz gefasst
Scoping Review in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Linda Battistuzzi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Truth Disclosure, Disclosure. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Prognostic disclosure enables shared decision-making by keeping patients informed about their health and involved in treatment-related choices. In metastatic cancer, patients who understand their prognosis are better placed to evaluate their health situation, have more realistic expectations about treatment, and better end-of-life (EoL) care. However, many oncologists feel uncomfortable discussing prognoses with their patients, as they worry about causing psychological distress and diminishing hope. Other barriers to prognostic disclosure are associated with the inherent uncertainty of prognostication, which is especially prominent in metastatic breast cancer (mBC), as are a lack of timely discussions about EoL care and poor quality of care at EoL. Despite this background, a preliminary literature search has shown that, to date, knowledge about prognostic disclosure in mBC has not been systematically mapped.
Objective
The overall aim of this scoping review will be to comprehensively explore the existing literature pertaining to prognostic disclosure in mBC.
Methods
This scoping review will follow Arksey and O’Malley’s expanded framework. We will systematically search electronic databases for peer-reviewed, published journal articles to identify appropriate studies. First, 2 members of the research team will independently review titles and abstracts. Then, they will review full texts to establish whether articles meet inclusion criteria. A data chart for collecting and sorting information will be developed. Results will be reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines and summarized quantitatively and qualitatively.
Results
We expect to present the results in a scoping review in 2025.
Conclusions
To our knowledge, this scoping review will be the first systematic effort aimed at mapping existing literature on prognostic disclosure in mBC, in which rapidly developing therapeutic approaches and changing disease trajectories generate new uncertainties and place new communicative demands on oncologists. The insights gained from this scoping review will inform the development of an interview schedule with oncologists, oncology residents, oncology nurses, and patients with mBC to explore their experiences, views, and perceptions about prognostic disclosure. International Registered Report Identifier (IRRID) PRR1-10.2196/57256
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
ORCID-Profile: Linda Battistuzzi, Irene Giannubilo, Claudia Bighin
Zitieren
APA
Battistuzzi, L., Giannubilo, I., & Bighin, C. (2025). Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review. JMIR Research Protocols. https://doi.org/10.2196/57256
Vancouver
Battistuzzi L, Giannubilo I, Bighin C. Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review. JMIR Research Protocols. 2025. doi:10.2196/57256
BibTeX
@article{Battistuzzi2025,
author = {Battistuzzi, Linda and Giannubilo, Irene and Bighin, Claudia},
title = {Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/57256}
}
EUVIMED